MatriChem Ltd. Unveils 3D Bioprinted Cancer Model Reproducing Tumor-Vessel Interface Dynamics for Drug Discovery

September 20, 2026

Euro-BioImaging Bulgaria

Overview

Bulgarian SME MatriChem Ltd., in collaboration with the Medical University of Plovdiv, has developed a novel 3D bioprinted cancer model, the ‘3DCAM platform,’ that accurately replicates the critical tumor-vessel interface. This platform integrates cancer cells, endothelial cells, and proprietary biomaterials into a structured 3D environment, allowing for enhanced study of tumor angiogenesis and metastasis. The innovation promises to significantly advance drug screening and personalized medicine by providing a more physiologically relevant experimental system.

In Depth

Key Findings

Bulgarian biotechnology company MatriChem Ltd., in partnership with the Medical University of Plovdiv, has successfully developed a 3D bioprinted cancer model, termed the ‘3DCAM platform,’ which precisely mimics the critical characteristics of the tumor-vessel interface. This innovative platform creates a structured 3D environment by combining cancer cells, endothelial cells, and proprietary extracellular matrix-like biomaterials, offering a more physiologically relevant system for studying tumor angiogenesis and metastasis. The model’s ability to faithfully replicate the complex interactions within the tumor microenvironment represents a significant advancement over traditional 2D culture methods.

Technical / Clinical Details

The 3DCAM platform leverages MatriChem’s unique hydrogel technology and high-resolution 3D bioprinting. This combination enables the fabrication of intricate 3D scaffolds that support cell growth and interaction within a controlled microenvironment. Advanced microscopy techniques, including confocal laser scanning microscopy and electron microscopy, are employed for the detailed validation and analysis of the model. These tools allow for real-time tracking of cellular morphology, proliferation, migration, and gene expression changes. The platform is particularly valuable for evaluating the efficacy and toxicity of anti-cancer drug candidates, especially those targeting angiogenesis, under conditions that are challenging to replicate with conventional 2D cultures or animal models.

Background & Context

Traditional cancer research has heavily relied on 2D cell cultures and animal models, both of which have limitations in fully replicating the complex human physiological environment. 3D cell culture systems, such as organoids and bioprinted models, are emerging as next-generation tools that provide more in vivo-like conditions, thereby improving the predictive accuracy of drug responses. MatriChem’s 3DCAM platform specifically addresses the critical aspect of tumor angiogenesis, a bottleneck in many oncology drug development programs, by offering a specialized model to study this process in detail.

Strategic Significance & Outlook

The 3DCAM platform is expected to lead to higher success rates in the early-stage screening of novel anti-cancer drug candidates. Furthermore, its capacity to incorporate patient-derived cancer cells opens avenues for personalized medicine, enabling the optimization of therapeutic choices based on individual patient biology. Beyond oncology, the technology holds promise for applications in regenerative medicine and the development of models for other diseases, positioning it as a fundamental technology within the evolving biotechnology landscape.

Source: https://www.eurobioimaging.eu/news/advanced-microscopy-supports-bulgarian-sme-in-developing-3d-bioprinted-cancer-model/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.